Elliott Investment Management Boosts Stake in Align Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy ALGN?
Source: Yahoo Finance
Align Technology's stock has risen 5.02% and reached a 5-day high, reflecting positive investor sentiment.
Elliott Investment Management has become one of Align Technology's largest investors, indicating a strategic intent to push for stock price improvement and potentially engage with management to explore options for enhancing share value. Analysts have noted that Align's stock has plummeted 75% since its record high in September 2021; however, shares jumped 4% in premarket trading following news of Elliott's investment, reflecting a market reassessment of its future potential. Additionally, Barclays upgraded Align Technology to Overweight, citing strong Q4 results and an attractive valuation, which further supports the positive outlook.
The engagement from Elliott Investment Management and the upgrade from Barclays suggest a renewed confidence in Align Technology's growth potential, particularly as the company aims for a revenue growth target of 3%-4% for 2026, driven by digital innovation and DSO momentum.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGN
Wall Street analysts forecast ALGN stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 190.070
Low
169.00
Averages
198.70
High
220.00
Current: 190.070
Low
169.00
Averages
198.70
High
220.00
About ALGN
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Align Technology Recognized as a Top 100 Global Innovator for Five Consecutive Years
- Global Innovator Recognition: Align Technology has been named a Top 100 Global Innovator for the fifth consecutive year in the 2026 LexisNexis Innovation Momentum report, highlighting its leadership and innovation capabilities in digital dentistry, thereby reinforcing its competitive advantage in the market.
- Patent Portfolio Growth: With over 3,000 active patents, Align's ongoing investments in key innovation areas such as AI-driven treatment planning, 3D printing advancements, and digital diagnostics enhance product functionality and design flexibility, solidifying its market position.
- Strong Technology Pipeline: Align's evolving technology pipeline aims to enhance treatment experiences through AI technologies, positively impacting both doctors and patients while expanding opportunities in the global $600 billion consumer market.
- Increased Industry Influence: The LexisNexis evaluation, based on an analysis of over 17 million global patents, underscores Align's continuous innovation, which not only boosts its industry influence but also lays the groundwork for future technological and industrial advancements.
See More
Align Technology Recognized as Top Global Innovator for Fifth Consecutive Year
- Global Innovator Recognition: Align Technology has been recognized as a Top 100 Global Innovator for the fifth consecutive year in the 2026 LexisNexis Innovation Momentum report, highlighting its leadership and ongoing investment in digital dentistry innovation.
- Growing Patent Portfolio: With over 3,000 active patents, Align's portfolio reflects significant R&D investments in key areas such as AI-driven treatment planning, 3D printing innovations, and digital diagnostics, further solidifying its competitive edge in the market.
- Strong Technology Pipeline: Align's evolving technology pipeline focuses on enhancing patient experiences through AI-driven diagnostic tools and real-time treatment planning, positioning the company at the forefront of the future of digital dentistry.
- Vast Market Opportunities: Align's technology solutions serve approximately 295,600 doctor customers and tap into a global consumer market of 600 million, having treated over 22.1 million patients, showcasing its immense potential in the digital dentistry sector.
See More
Wall Street's Perspective on Three Stocks
- Teradata's Dim Outlook: With a consensus price target of $35.73 suggesting a 40.2% implied return, Teradata's flat billings over the past year indicate weak demand, leading to stagnant sales projections for the next 12 months, which reflects a lack of market appeal.
- Align Technology's Growth Struggles: Align Technology has a consensus price target of $201.69 with an 18.2% implied return; however, its annual revenue growth of only 2.2% over the past two years falls short of healthcare sector standards, and a 5.3 percentage point decline in adjusted operating margin signals deteriorating profitability.
- Elanco's Challenges: Elanco's consensus price target stands at $28.77, implying a 24.7% return, yet its muted 3.3% annual revenue growth over the last two years, coupled with rising costs outpacing revenue, has led to a 3.3 percentage point drop in adjusted operating margin, indicating ineffective cost management during expansion.
- Market Opportunity Analysis: While these three stocks receive positive ratings on Wall Street, their fundamentals reveal potential risks, prompting investors to seek stocks with greater growth potential to avoid losses amid market volatility.
See More
Align Technology to Report Q1 2026 Financial Results
- Earnings Release Schedule: Align Technology announced it will report its Q1 2026 financial results on April 29, 2026, after market close at 4:00 p.m. ET, reflecting the company's commitment to transparent communication with stakeholders.
- Conference Call Details: Following the earnings release, Align will host a conference call at 4:30 p.m. ET to discuss the financial results, indicating the company's intent to enhance investor confidence through direct engagement and transparency.
- Product Overview: Align's Invisalign® system is the most advanced clear aligner system globally, serving approximately 295,600 doctor customers, showcasing its leadership in digital orthodontics and restorative dentistry.
- Market Opportunity: Align's products and services provide access to a 600 million consumer market opportunity, having treated around 22.1 million patients over the past 29 years, highlighting its ongoing innovation and market potential in digital dentistry.
See More
Global Markets Decline Amid Inflation Concerns
- Market Decline: On Thursday, the S&P 500 fell by 0.27%, the Dow Jones Industrial Average by 0.44%, and the Nasdaq 100 by 0.29%, indicating a broad market decline driven by inflation concerns and investor pessimism.
- Energy Price Volatility: Crude oil prices experienced significant fluctuations as WTI initially rallied before retreating after Israel's assistance to the US in opening the Strait of Hormuz, highlighting the direct impact of geopolitical tensions on energy markets.
- Rising Bond Yields: The 10-year German Bund yield rose to a 2.25-year high of 3.01%, while the 10-year US Treasury yield reached a 6.75-month high of 4.32%, reflecting market expectations of potential tightening monetary policies by central banks, which could increase borrowing costs.
- Economic Data Impact: US weekly initial jobless claims unexpectedly fell to 205,000, indicating a strong labor market, while the Philadelphia Fed business outlook survey unexpectedly rose to a 6-month high of 18.1, further intensifying market concerns over potential interest rate hikes.
See More
Elliott Investment Management Builds Stake in Align Technology
- Investor Stake Increase: Elliott Investment Management has become one of Align Technology's largest investors, indicating a strategic intent to push for stock price improvement and potentially engage with management to explore options for enhancing share value.
- Stock Price Decline: Align's stock has sharply fallen from its 2021 peak of $729.92 to a recent close of $172.41, reflecting a market value of approximately $12.3 billion, which highlights a significant drop in demand following a surge in cosmetic dental treatments during the pandemic.
- Signs of Market Stabilization: Barclays analysts noted in a February 4 report that dental markets may be finding a floor this year, suggesting that Align could recover some lost valuation, with potential trading closer to 12 times EBITDA compared to around 10 times currently, indicating possible upside.
- Historical Valuation Comparison: Although Align's valuation remains below historical averages of 17 and 21 times over three- and five-year periods, respectively, improving market conditions could yield higher returns for investors, particularly as factors related to its Israel manufacturing operations evolve.
See More
Align Technology Recognized as a Top 100 Global Innovator for Five Consecutive Years
- Global Innovator Recognition: Align Technology has been named a Top 100 Global Innovator for the fifth consecutive year in the 2026 LexisNexis Innovation Momentum report, highlighting its leadership and innovation capabilities in digital dentistry, thereby reinforcing its competitive advantage in the market.
- Patent Portfolio Growth: With over 3,000 active patents, Align's ongoing investments in key innovation areas such as AI-driven treatment planning, 3D printing advancements, and digital diagnostics enhance product functionality and design flexibility, solidifying its market position.
- Strong Technology Pipeline: Align's evolving technology pipeline aims to enhance treatment experiences through AI technologies, positively impacting both doctors and patients while expanding opportunities in the global $600 billion consumer market.
- Increased Industry Influence: The LexisNexis evaluation, based on an analysis of over 17 million global patents, underscores Align's continuous innovation, which not only boosts its industry influence but also lays the groundwork for future technological and industrial advancements.
See More
Align Technology Recognized as Top Global Innovator for Fifth Consecutive Year
- Global Innovator Recognition: Align Technology has been recognized as a Top 100 Global Innovator for the fifth consecutive year in the 2026 LexisNexis Innovation Momentum report, highlighting its leadership and ongoing investment in digital dentistry innovation.
- Growing Patent Portfolio: With over 3,000 active patents, Align's portfolio reflects significant R&D investments in key areas such as AI-driven treatment planning, 3D printing innovations, and digital diagnostics, further solidifying its competitive edge in the market.
- Strong Technology Pipeline: Align's evolving technology pipeline focuses on enhancing patient experiences through AI-driven diagnostic tools and real-time treatment planning, positioning the company at the forefront of the future of digital dentistry.
- Vast Market Opportunities: Align's technology solutions serve approximately 295,600 doctor customers and tap into a global consumer market of 600 million, having treated over 22.1 million patients, showcasing its immense potential in the digital dentistry sector.
See More
Wall Street's Perspective on Three Stocks
- Teradata's Dim Outlook: With a consensus price target of $35.73 suggesting a 40.2% implied return, Teradata's flat billings over the past year indicate weak demand, leading to stagnant sales projections for the next 12 months, which reflects a lack of market appeal.
- Align Technology's Growth Struggles: Align Technology has a consensus price target of $201.69 with an 18.2% implied return; however, its annual revenue growth of only 2.2% over the past two years falls short of healthcare sector standards, and a 5.3 percentage point decline in adjusted operating margin signals deteriorating profitability.
- Elanco's Challenges: Elanco's consensus price target stands at $28.77, implying a 24.7% return, yet its muted 3.3% annual revenue growth over the last two years, coupled with rising costs outpacing revenue, has led to a 3.3 percentage point drop in adjusted operating margin, indicating ineffective cost management during expansion.
- Market Opportunity Analysis: While these three stocks receive positive ratings on Wall Street, their fundamentals reveal potential risks, prompting investors to seek stocks with greater growth potential to avoid losses amid market volatility.
See More
Align Technology to Report Q1 2026 Financial Results
- Earnings Release Schedule: Align Technology announced it will report its Q1 2026 financial results on April 29, 2026, after market close at 4:00 p.m. ET, reflecting the company's commitment to transparent communication with stakeholders.
- Conference Call Details: Following the earnings release, Align will host a conference call at 4:30 p.m. ET to discuss the financial results, indicating the company's intent to enhance investor confidence through direct engagement and transparency.
- Product Overview: Align's Invisalign® system is the most advanced clear aligner system globally, serving approximately 295,600 doctor customers, showcasing its leadership in digital orthodontics and restorative dentistry.
- Market Opportunity: Align's products and services provide access to a 600 million consumer market opportunity, having treated around 22.1 million patients over the past 29 years, highlighting its ongoing innovation and market potential in digital dentistry.
See More
Global Markets Decline Amid Inflation Concerns
- Market Decline: On Thursday, the S&P 500 fell by 0.27%, the Dow Jones Industrial Average by 0.44%, and the Nasdaq 100 by 0.29%, indicating a broad market decline driven by inflation concerns and investor pessimism.
- Energy Price Volatility: Crude oil prices experienced significant fluctuations as WTI initially rallied before retreating after Israel's assistance to the US in opening the Strait of Hormuz, highlighting the direct impact of geopolitical tensions on energy markets.
- Rising Bond Yields: The 10-year German Bund yield rose to a 2.25-year high of 3.01%, while the 10-year US Treasury yield reached a 6.75-month high of 4.32%, reflecting market expectations of potential tightening monetary policies by central banks, which could increase borrowing costs.
- Economic Data Impact: US weekly initial jobless claims unexpectedly fell to 205,000, indicating a strong labor market, while the Philadelphia Fed business outlook survey unexpectedly rose to a 6-month high of 18.1, further intensifying market concerns over potential interest rate hikes.
See More
Elliott Investment Management Builds Stake in Align Technology
- Investor Stake Increase: Elliott Investment Management has become one of Align Technology's largest investors, indicating a strategic intent to push for stock price improvement and potentially engage with management to explore options for enhancing share value.
- Stock Price Decline: Align's stock has sharply fallen from its 2021 peak of $729.92 to a recent close of $172.41, reflecting a market value of approximately $12.3 billion, which highlights a significant drop in demand following a surge in cosmetic dental treatments during the pandemic.
- Signs of Market Stabilization: Barclays analysts noted in a February 4 report that dental markets may be finding a floor this year, suggesting that Align could recover some lost valuation, with potential trading closer to 12 times EBITDA compared to around 10 times currently, indicating possible upside.
- Historical Valuation Comparison: Although Align's valuation remains below historical averages of 17 and 21 times over three- and five-year periods, respectively, improving market conditions could yield higher returns for investors, particularly as factors related to its Israel manufacturing operations evolve.
See More
